IP Library Granted Patent US 9,157,875
Granted Patent B2
US 9,157,875 · App. 10/880,388 · Granted Oct 13, 2015

Drug development and manufacturing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,157,875
App. No.
10/880,388
Granted
Oct 13, 2015
Kind
B2
Abstract

X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical, for estimating the binding selectivity of a chemical versus chemical analogs, for measuring post-translational modifications of proteins, and for drug manufacturing.

Claims (12)

1. A method for detecting a binding event of at least one chemical having at least one heavy element to at least one receptor, comprising:

exposing the at least one bead-supported receptor to X-ray radiation by means of a micro-X-ray fluorescence spectrometer prior to exposing the at least one receptor to the at least one chemical to be tested for binding to the at least one receptor;

measuring the X-ray fluorescence signal intensity of the at least one receptor;

combining the at least one bead-supported receptor and the at least one chemical then allowing a receptor-chemical complex to form; wherein the at least one chemical comprises at least one heavy element selected from the group consisting of P, Cl, F, S, and Br;

removing any at least one chemical that is not part of the receptor-chemical complex;

exposing the receptor-chemical complex to X-ray radiation from an X-ray excitation source;

measuring the X-ray fluorescence signal intensity of the at least one heavy element in the receptor-chemical complex; and

evaluating the receptor-chemical complex X-ray fluorescence signal intensity such that when the heavy element is present in both the at least one chemical and the at least one receptor, an assessed difference in the X-ray signal intensities of the receptor-chemical complex and the at least one receptor signifies that a binding event has occurred between the at least one chemical and the at least one receptor; and when the heavy element is only present in the at least one chemical but not the at least one receptor, the X-ray signal intensity of the receptor-chemical complex signifies that a binding event has occurred between the at least one chemical and the at least one receptor.

2. The method of claim 1 wherein the at least one chemical comprises more than one chemical.

3. The method of claim 1 wherein the at least one heavy element comprises more than one heavy element selected from the group consisting of P, Cl, F, S, and Br.

4. The method of claim 1 wherein the at least one chemical comprises more than one chemical, wherein the at least one bead-supported receptor comprises more than one bead-supported receptor and wherein the at least one heavy element comprises more than one heavy element selected from the group consisting of P, Cl, F, S, and Br.

5. The method of claim 4 wherein each at least one chemical binds to at least one receptor with different affinities.

Assignments (16)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2022
From: ICAGEN, INC.; ICAGEN CORP.; XRPRO SCIENCES, INC.; CALDERA DISCOVERY, INC.
To: ADJACENT ACQUISITION CO., LLC
Reel/Frame 059269/0422 →
CHANGE OF NAME Recorded Mar 15, 2022
From: ADJACENT ACQUISITION CO., LLC
To: ICAGEN, LLC
Reel/Frame 059366/0969 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 052304/0304 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 052304/0712 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 047046/0311 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 047046/0214 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047317/0860 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047016/0859 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; ICAGEN-T, INC.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042378/0935 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042379/0067 →
CHANGE OF NAME Recorded Jan 28, 2016
From: XRPRO SCIENCES, INC.
To: ICAGEN, INC.
Reel/Frame 037638/0543 →
CHANGE OF NAME Recorded Apr 9, 2015
From: CALDERA PHARMACEUTICALS, INC
To: XRPRO SCIENCES, INC.
Reel/Frame 035401/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2014
From: LOS ALAMOS NATIONAL SECURITY, LLC
To: CALDERA PHARMACEUTICALS, INC.
Reel/Frame 033961/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2006
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: LOS ALAMOS NATIONAL SECURITY, LLC
Reel/Frame 017910/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2005
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 015835/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2005
From: WERNER, BENJAMIN P.; MCCLESKEY, T MARK; BURRELL, ANTHONY K.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Reel/Frame 016230/0179 →